Thyroid cancer: pathogenesis and targeted therapy

Therapeutic options for advanced, unresectable radioiodine-resistant thyroid cancers have historically been limited. Recent progress in understanding the pathogenesis of the various subtypes of thyroid cancer has led to increased interest in the development of targeted therapies, with potential strategies including angiogenesis inhibition, inhibition of aberrant intracellular signaling in the MAPK and PI3K/AKT/mTOR pathways, radioimmunotherapy, and redifferentiation agents. On the basis of a recent positive phase III clinical trial, the RET, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR) inhibitor vandetanib has received FDA approval as of April 2011 for use in the treatment of advanced medullary thyroid cancer. Several other recent phase II clinical trials in advanced thyroid cancer have demonstrated significant activity, and multiple other promising therapeutic strategies are in earlier phases of clinical development. The recent progress in targeted therapy is already revolutionizing management paradigms for advanced thyroid cancer, and will likely continue to dramatically expand treatment options in the coming years.

[1]  R. Tuttle,et al.  Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. , 2001, Surgery.

[2]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[3]  G. Chiappetta,et al.  Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. , 1996, Oncogene.

[4]  A. Ravaud,et al.  Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. , 2010, The oncologist.

[5]  P. Ladenson,et al.  Quantitative assessment of promoter methylation profiles in thyroid neoplasms. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  N. Mitsiades,et al.  Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. , 2006, The Journal of clinical endocrinology and metabolism.

[7]  K. D. Williams,et al.  Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. , 2007, Thyroid : official journal of the American Thyroid Association.

[8]  F. Raue,et al.  Medullary Thyroid Carcinoma , 2021, Recent Results in Cancer Research.

[9]  E. Kebebew,et al.  Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[10]  Y. Nikiforov.  RET/PTC rearrangement in thyroid tumors , 2002, Endocrine pathology.

[11]  Weijing Sun,et al.  Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Ladenson,et al.  Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. , 2003, Cancer research.

[13]  M. Ratain,et al.  Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. , 2010 .

[14]  R. Domingues,et al.  Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas , 2009, British Journal of Cancer.

[15]  G. Fuller,et al.  RET Oncogene Activation in Papillary Thyroid Carcinoma , 2001, Advances in anatomic pathology.

[16]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[17]  W. Scherbaum,et al.  Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  D. Hochbaum,et al.  Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. , 2010, Cancer research.

[19]  R. Wahl,et al.  Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. , 2005, Endocrine-related cancer.

[20]  C. Higgins,et al.  Octreotide therapy in advanced thyroid cancer. , 1994, Thyroid : official journal of the American Thyroid Association.

[21]  M. Saji,et al.  Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. , 2003, Annals of clinical and laboratory science.

[22]  A. de Leiva,et al.  PTEN promoter methylation in sporadic thyroid carcinomas. , 2006, Thyroid : official journal of the American Thyroid Association.

[23]  A. Abdel‐Mageed,et al.  BRAF mutation in papillary thyroid carcinoma. , 2012, International journal of clinical and experimental medicine.

[24]  D. Chaplin,et al.  Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. , 1999, Anticancer research.

[25]  J. Moley,et al.  Sporadic and familial medullary thyroid carcinoma: state of the art. , 2009, The Surgical clinics of North America.

[26]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[27]  Thomas J Lynch,et al.  A phase II study of gefitinib in patients with advanced thyroid cancer. , 2008, Thyroid : official journal of the American Thyroid Association.

[28]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[29]  X. Qian,et al.  RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors , 2005, Laboratory Investigation.

[30]  E. Mazzaferri.  An overview of the management of papillary and follicular thyroid carcinoma. , 1999, Thyroid : official journal of the American Thyroid Association.

[31]  M. Saji,et al.  AKT in thyroid tumorigenesis and progression. , 2007, Endocrinology.

[32]  A. Sakamoto,et al.  Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. , 2000, Pathology, research and practice.

[33]  E. Baudin,et al.  Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). , 2010 .

[34]  L. Bastholt,et al.  Motesanib diphosphate in progressive differentiated thyroid cancer. , 2008, The New England journal of medicine.

[35]  S. Delorme,et al.  Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. , 2007, European journal of endocrinology.

[36]  R. Herbst,et al.  Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  V. Vasko,et al.  Specific pattern of RAS oncogene mutations in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[38]  Q. Duh,et al.  Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. , 1996, Surgery.

[39]  A. Pinchera,et al.  Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. , 2006, Endocrine-related cancer.

[40]  L. Bresler*,et al.  Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. , 1999, The Journal of endocrinology.

[41]  M. Schlumberger,et al.  Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[42]  B. Goh,et al.  Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. , 2010, The Lancet. Oncology.

[43]  Radiology,et al.  Clinical Cancer esearch cer Therapy : Clinical se II Study of Daily Sunitinib in FDG-PET – Positive , ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid R Functional Imaging Correlation , 2010 .

[44]  C. Rochlitz,et al.  [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. , 2009, Cancer.

[45]  R. Kurzrock,et al.  Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. , 2011, The Journal of clinical endocrinology and metabolism.

[46]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[47]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[48]  M. Santoro,et al.  BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma , 2006, Clinical Cancer Research.

[49]  G. Tell,et al.  Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. , 2005, Endocrinology.

[50]  M. Schlumberger,et al.  Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy , 1990, Tumori.

[51]  Jiachao Liang,et al.  Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Wanders,et al.  A phase I study of E7080 in patients (pts) with advanced malignancies , 2008 .

[53]  Z. Hall.  Cancer , 1906, The Hospital.

[54]  S. Jhiang,et al.  The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation , 2002, Oncogene.

[55]  S. Wajner,et al.  Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. , 2010, Thyroid : official journal of the American Thyroid Association.

[56]  D. Pastuszak-Lewandoska,et al.  A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. , 2011, Frontiers in bioscience.

[57]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[58]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[59]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[60]  D. Schoenfeld,et al.  A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma , 1985, Cancer.

[61]  D. Hayes,et al.  Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. , 2010 .

[62]  D. Grimm,et al.  Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. , 2004, Endocrinology.

[63]  Lei Zhang,et al.  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.

[64]  E. Vokes,et al.  Phase II trial of sunitinib in medullary thyroid cancer (MTC). , 2010 .

[65]  A. Ryan,et al.  ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. , 2005, Cancer research.

[66]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[67]  M. Morgan,et al.  Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? , 2000, Blood.

[68]  M. Grever,et al.  Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[69]  N. Togashi,et al.  Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. , 2008, European journal of cancer.

[70]  Ming-Chih Crouthamel,et al.  Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity , 2007, Molecular Cancer Therapeutics.

[71]  M. Huijberts,et al.  Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. , 2009, European journal of endocrinology.

[72]  K. D. Williams,et al.  Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results , 2008 .

[73]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[74]  J. Copland,et al.  Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1 , 2006, Oncogene.

[75]  E. Vokes,et al.  Phase 2 study of sunitinib in refractory thyroid cancer , 2008 .

[76]  T. Giordano,et al.  A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.

[77]  Ling Wang,et al.  AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. , 2006, Cancer research.

[78]  V. Leite,et al.  High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. , 2011, The Journal of clinical endocrinology and metabolism.

[79]  K. Kuzdak,et al.  Evaluation of the levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[80]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  V. Trovisco,et al.  BRAF mutations are associated with some histological types of papillary thyroid carcinoma , 2004, The Journal of pathology.

[82]  J. Drevs,et al.  Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors , 2005 .

[83]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[84]  M. Willingham,et al.  Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. , 2007, Carcinogenesis.

[85]  T. Endo,et al.  Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. , 2004, Endocrinology.

[86]  M. Xing,et al.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.

[87]  G. Viglietto,et al.  RET/PTC oncogene activation is an early event in thyroid carcinogenesis. , 1995, Oncogene.

[88]  J. Fagin,et al.  Genetic and epigenetic alterations of the cyclin‐dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas , 1998, Cancer.

[89]  Tae Yong Kim,et al.  The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma , 2005 .

[90]  L. Paz-Ares,et al.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[91]  V. Trovisco,et al.  BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas , 2004, Virchows Archiv.

[92]  M. Xing,et al.  Gene methylation in thyroid tumorigenesis. , 2007, Endocrinology.

[93]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[94]  M. Schott,et al.  Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer , 2011 .

[95]  R. Camp,et al.  ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[97]  M. Tachibana,et al.  Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. , 1998, American journal of surgery.

[98]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[99]  M. Bibby,et al.  In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug , 1999, British Journal of Cancer.

[100]  G. Schwartz,et al.  A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[102]  P. Marks,et al.  Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer , 2005, Clinical Cancer Research.

[103]  Giancarlo Troncone,et al.  The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. , 2010, Endocrine-related cancer.

[104]  E. Voest,et al.  A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[105]  L. Einhorn,et al.  Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.

[106]  D. Sidransky,et al.  BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment , 2004, Modern Pathology.

[107]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  M. Santoro,et al.  RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. , 2006, European journal of endocrinology.

[109]  L. Bastholt,et al.  Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  N. Eberhardt,et al.  The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.

[111]  M. Santoro,et al.  Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. , 1999, Oncology research.

[112]  M. Yatin,et al.  Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. , 1999, The Journal of clinical endocrinology and metabolism.

[113]  M. Schott.  Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 , 2008 .

[114]  G. Chiappetta,et al.  Mutated human kirsten ras, driven by a thyroglobulin promoter, induces a growth advantage and partially dedifferentiates rat thyroid epithelial cells in vitro , 1995, International journal of cancer.

[115]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[116]  M. Saji,et al.  Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. , 2002, Thyroid : official journal of the American Thyroid Association.

[117]  H. Stambuk,et al.  Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  Tae Yong Kim,et al.  The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. , 2005, Clinical endocrinology.

[119]  P. Fu,et al.  A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. , 2009, Thyroid : official journal of the American Thyroid Association.

[120]  M. Fleisher,et al.  Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. , 2002, The Journal of clinical endocrinology and metabolism.

[121]  A. El‐Naggar,et al.  Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer , 2007, Clinical Cancer Research.

[122]  E. Kebebew,et al.  Anaplastic thyroid carcinoma , 2005, Cancer.

[123]  C. Rochlitz,et al.  [90Yttrium‐DOTA]‐TOC response is associated with survival benefit in iodine‐refractory thyroid cancer , 2009, Cancer.

[124]  Ge Zhou,et al.  Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model , 2011, Clinical Cancer Research.

[125]  H. Namba,et al.  Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.

[126]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  Q. Duh,et al.  Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. , 1997, The Journal of clinical endocrinology and metabolism.

[128]  J. Copland,et al.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[129]  Y. Nobuhara,et al.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines , 2005, British Journal of Cancer.

[130]  Peng Hou,et al.  Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. , 2009, Cancer research.

[131]  M. Saji,et al.  Overexpression and overactivation of Akt in thyroid carcinoma. , 2001, Cancer research.